Olema Pharmaceuticals (OLMA) Enterprise Value (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Enterprise Value of -$505.3 million for Q1 2026, down 28.68% year-over-year from -$708.6 million in Q1 2025, and little changed quarter-over-quarter from -$505.4 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Enterprise Value (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Enterprise Value for 7 consecutive years, with -$505.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value fell 28.68% year-over-year to -$505.3 million; the TTM figure through Mar 2026 stood at -$505.3 million (down 28.68% YoY), while the FY2025 annual figure was -$505.4 million, down 16.44% from the prior year.
- Enterprise Value steadied at -$505.3 million in Q1 2026 per OLMA's latest filing, from -$505.4 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$167.4 million in Q2 2023 and bottomed at -$505.4 million in Q4 2025.
- Historically, Enterprise Value has averaged -$297.6 million across 5 years, with a median of -$261.8 million in 2023.
- Annual changes were most pronounced in 2023 — Enterprise Value surged 30.58% — and 2024, when it tumbled 65.8%.
- Olema Pharmaceuticals' Enterprise Value stood at -$204.4 million in 2022, then declined by 28.07% to -$261.8 million in 2023, then sank by 65.8% to -$434.1 million in 2024, then declined by 16.44% to -$505.4 million in 2025, then gained by 0.02% to -$505.3 million in 2026.
- Business Quant data shows OLMA's Enterprise Value at -$505.3 million in Q1 2026, -$505.4 million in Q4 2025, and -$329.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | -461.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -461.07 Mn |
| Mar 31, 2026 | -505.35 Mn |
| Dec 31, 2025 | -505.44 Mn |
| Sep 30, 2025 | -328.96 Mn |
| Jun 30, 2025 | -361.91 Mn |
| Mar 31, 2025 | -392.71 Mn |
| Dec 31, 2024 | -434.09 Mn |
| Sep 30, 2024 | -214.76 Mn |
| Jun 30, 2024 | -239.10 Mn |
| Mar 31, 2024 | -248.98 Mn |
| Dec 31, 2023 | -261.81 Mn |
| Sep 30, 2023 | -276.90 Mn |
| Jun 30, 2023 | -167.44 Mn |
| Mar 31, 2023 | -185.95 Mn |
| Dec 31, 2022 | -204.42 Mn |
| Sep 30, 2022 | -222.60 Mn |
| Jun 30, 2022 | -240.71 Mn |
| Mar 31, 2022 | -267.87 Mn |
| Dec 31, 2021 | -287.25 Mn |
| Sep 30, 2021 | -305.95 Mn |